Gregory A. Daniels, MD, PhD

Gregory A. Daniels, MD, PhD, associate clinical professor of medicine, Division of Hematology-Oncology, University of California, San Diego, discusses opportunities to combine immunotherapies with both targeted therapies and other immunotherapies. Daniels references the results of the 2007-2012 PROCLAIM National Registry, which was presented at the 2014 ASCO Annual Meeting.

Articles

Gregory A. Daniels, MD, PhD, discusses opportunities to combine immunotherapies with both targeted therapies and other immunotherapies.

Combining Immunotherapies With Targeted Therapies and Other Immunotherapies

Gregory A. Daniels, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, University of California, San Diego, discusses the findings of the 2007-2012 PROCLAIM national registry.

IL-2 is an immunotherapy that can give complete responses that last years

The database retrospectively looked back over a 5-year period

The registry showed that IL-2 still gives an occasional, durable response

The registry also showed that clinical factors such as normal LDH and patient performance status is important in determining who will be successful on IL-2

Patients with stable disease or did not seem to respond to IL-2 initially had better overall survival than previously thought, according to the registry findings

Gregory A. Daniels, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, University of California, San Diego, discusses the findings of the 2007-2012 PROCLAIM national registry

Gregory A. Daniels, MD, PhD | Authors

Articles

Combining Immunotherapies With Targeted Therapies and Other Immunotherapies

An Analysis of the PROCLAIM 2007-2012 National Registry